Amendment 6: DRIVe EZ Broad Agency Announcement

Office of Biomedical Advanced Research and Development
Authority (BARDA) Division of Research, Innovation & Ventures

(DRIVe)

Amendment 006 Issuance for Easy Broad Agency Announcement

(EZ-BAA) BAA-22-100-SOL-00003

The purpose of this Amendment is the following:

1) Update the closing date for the following Area of
Interest (AOI):
AOI #19: Healing Lungs
2) Update the closing date for the following Area of
Interest (AOI):
AOI #17: Digital MCMs
3) Update the closing date for the following Area of
Interest (AOI):
AOI #16: Lab at Home
4) Revise the following Area of Interest (AOI):
AOI #16: Lab at Home

INTRODUCTION AND OVERVIEW INFORMATION

A. Development Opportunity Objective:

Under this Amendment, DRIVe is doing the following:
1)

Updating the closing date for the following research Area of Interest (AOI): AOI #19: Healing Lungs

2)

Updating the closing date for the following research Area of Interest (AOI): AOI #17: Digital MCMs

3)

Updating the closing date for the following research Area of Interest (AOI): AOI #16: Lab at Home

4)

Revising the following research Area of Interest (AOI): AOI#16: Lab at Home

We are seeking abstract submissions for the following revised AOI: AOI #16: Lab at Home
DRIVe is seeking proposals to develop novel platform technologies and instrumentation for on-demand detection of multiple biochemical health markers at the point of need. The goal is to obtain (quantitative) information about patients’ health status at the point of need without going through traditional central laboratory testing, which requires laboratory skills, long turn-around times, and can lead to delays in receiving care. Such platforms could enhance the capabilities of point-of-care medicine by enabling datadriven diagnoses by physicians without requiring sample shipping or travel to a sample collection site. Enabling such testing could greatly enhance infection detection, chronic disease management, clinical trial management etc., leading to a healthier population with reduced healthcare costs. The instrumentation / platform technologies developed through this program are primarily intended for settings such as the home, but could also be useful in doctor’s offices, nursing homes, or immediate care facilities, where access to analytical results at the point of need is vital. While DRIVe does not specify a particular platform form factor or sensing modality and will consider both desktop (portable) and wearable platforms, a successful platform technology will provide single time point